Anzeige
Meldung des Tages: „Echte Revolution“: Dieses MedTech-Unternehmen greift nach dem Milliardenmarkt

Savara Aktie News

Aktie
WKN:  A2DQ2B ISIN:  US8051111016 US-Symbol:  SVRA Branche:  Biotechnologie Land:  USA
5,50 €
+0,00 €
0,00%
23.12.25
Depot/Watchlist
Marktkapitalisierung *
1,05 Mrd. €
Streubesitz
11,74%
KGV
-6,40
Index-Zuordnung
-

Savara News

22.12.25 - Businesswire
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the ...
17.12.25 - Businesswire
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management ...
11.12.25 - Businesswire
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its ...
02.12.25 - Businesswire
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has ...
20.11.25 - Businesswire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management ...
12.11.25 - Businesswire
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending ...
07.11.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders PR Newswire
07.11.25 - PR Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara PR Newswire
07.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
07.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
06.11.25 - PR Newswire
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA PR Newswire
04.11.25 - PR Newswire
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.11.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA PR Newswire
03.11.25 - Businesswire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management ...
03.11.25 - PR Newswire
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA PR Newswire
03.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
03.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
02.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit PR Newswire
31.10.25 - Businesswire
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced ...
31.10.25 - PR Newswire
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA PR Newswire

Newssuche

Videos

newspaper
16.12.25 +1,32%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Kein Weihnachtswunder
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Blutuntersuchung ohne Blutabnahme!
Mehr zur Aktie »